뉴스

• Diagnostics Rally Despite Kolon TissueGene Trial Shock[K-Bio Pulse] Investor sentiment across South Korea’s pharmaceutical and life sciences sectors remained weak on July 22 following the Phase 3 setback for Kolon TissueGene’s osteoarthritis candidate TG-... www.edaily.co.kr · 2026.07.23